MEDICINOVA INC
MNOV · XNASCIK 1226616fmd_1V9XFPVVKJZX5XDWRP8YHJQ3GZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2005 to Sep 30, 2026, 71 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 4 | – | 1 | – | 0 |
| Research and development | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 5 | 7 | 7 |
| Total operating expenses | 11 | 13 | 16 | 14 | 14 | 14 | 15 | 11 | 13 | 14 |
| Operating income | (11) | (13) | (16) | (14) | (14) | (10) | (15) | (10) | (13) | (13) |
| Interest expense | 0 | 0 | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (1) | (0) | (0) |
| Income before taxes | (11) | (13) | (15) | (13) | (14) | (10) | (14) | (9) | (11) | (12) |
| Income tax expense | 0 | (2) | 0 | 0 | (0) | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (11) | (11) | (15) | (13) | (14) | (10) | (14) | (9) | (11) | (12) |
| Net income | (11) | (11) | (15) | (13) | (14) | (10) | (14) | (9) | (11) | (12) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |